Executive Retention Agreements between Myriad Genetics, Inc. and Executive Officers
Myriad Genetics, Inc. has entered into standard Executive Retention Agreements with several of its executive officers, including presidents and key executives of its subsidiaries. These agreements outline the terms under which the executives will be retained by the company, including any amendments made over time. The agreements are designed to ensure the continued employment of these executives, likely providing terms related to retention, compensation, and conditions for termination or change of control. The listed execution and amendment dates indicate ongoing updates to the agreements.
Exhibit 10.1
Attachment
Each of the following executive officers of Myriad Genetics, Inc. has entered into the Company’s standard form Executive Retention Agreement.
| Executive Officer | Execution Date |
| Mark C. Capone, President and Chief Executive Officer | November 17, 2006, as amended October 12, 2007, and further amended September 29, 2015 |
| Alexander Ford, President, Myriad Genetic Laboratories, Inc. | July 1, 2015, as amended September 29, 2015 |
| Gary A. King, EVP International Operations | July 8, 2010, as amended September 29, 2015 |
| Jerry S. Lanchbury, Ph.D., Chief Scientific Officer | February 17, 2005, as amended October 12, 2007, and further amended September 29, 2015 |
| Richard M. Marsh, Esq., EVP, General Counsel and Secretary | February 17, 2005, as amended October 12, 2007, and further amended September 29, 2015 |
| Ralph L. McDade, President, Myriad RBM, Inc. | September 29, 2015 |
| R. Bryan Riggsbee, Chief Financial Officer and Treasurer | December 18, 2014, as amended September 29, 2015 |
| Bernard F. Tobin, President, Crescendo Biosciences, Inc. | December 19, 2014, as amended September 29, 2015 |
| Mark Verratti, President, Assurex Health, Inc. | September 19, 2017 |
